{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:02:01Z","timestamp":1781776921641,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":884,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1124\/jpet.122.001208","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T10:50:26Z","timestamp":1656413426000},"page":"208-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy"],"prefix":"10.1016","volume":"382","author":[{"given":"Pierre-Axel","family":"Monternier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Parasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Theurey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Gluais Dagorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navtej","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavarekere N","family":"Nagaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Fouqueray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hallakou-Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001208_bib1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddi140","article-title":"Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy","volume":"14","author":"Asheuer","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jneumeth.2003.10.016","article-title":"Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice","volume":"134","author":"Beirowski","year":"2004","journal-title":"J Neurosci Methods"},{"key":"10.1124\/jpet.122.001208_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biochi.2013.11.023","article-title":"Pathophysiology of X-linked adrenoleukodystrophy","volume":"98","author":"Berger","year":"2014","journal-title":"Biochimie"},{"key":"10.1124\/jpet.122.001208_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.101","article-title":"Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening","volume":"49","author":"Bezman","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.122.001208_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/jpet.122.001208_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-7-51","article-title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management","volume":"7","author":"Engelen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/jpet.122.001208_bib7","article-title":"Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study","volume":"2","author":"Fouqueray","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1124\/jpet.122.001208_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.biochi.2013.09.012","article-title":"Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy","volume":"98","author":"Fourcade","year":"2014","journal-title":"Biochimie"},{"key":"10.1124\/jpet.122.001208_bib9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1089\/ars.2010.3877","article-title":"Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy","volume":"15","author":"Galino","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.122.001208_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0092-8674(92)90591-Y","article-title":"Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons","volume":"71","author":"Giese","year":"1992","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001208_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep4.1799","article-title":"Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis","volume":"6","author":"Gluais-Dagorn","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1124\/jpet.122.001208_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ana.25085","article-title":"Microglial dysfunction as a key pathological change in adrenomyeloneuropathy","volume":"82","author":"Gong","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.122.001208_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/nan.12399","article-title":"Heat shock protein expression in cerebral X-linked adrenoleukodystrophy reveals astrocyte stress prior to myelin loss","volume":"44","author":"G\u00f6rtz","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1124\/jpet.122.001208_bib52","series-title":"Mood and Anxiety Related Phenotypes in Mice, in Neuromethods","first-page":"1","article-title":"The open field test","author":"Gould","year":"2009"},{"key":"10.1124\/jpet.122.001208_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1210\/en.2016-1842","article-title":"A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy","volume":"158","author":"Hartley","year":"2017","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.122.001208_bib15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/hmg\/ddn066","article-title":"Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture","volume":"17","author":"Hein","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.122.001208_bib17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"10.1124\/jpet.122.001208_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1471-4159.1976.tb04461.x-i1","article-title":"Fatty acid abnormality in adrenoleukodystrophy","volume":"26","author":"Igarashi","year":"1976","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.122.001208_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.bbadis.2012.03.012","article-title":"X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects","volume":"1822","author":"Kemp","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.122.001208_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrendo.2016.90","article-title":"Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history","volume":"12","author":"Kemp","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/jpet.122.001208_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/3242","article-title":"Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy","volume":"4","author":"Kemp","year":"1998","journal-title":"Nat Med"},{"key":"10.1124\/jpet.122.001208_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and molecular mechanisms of metformin action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.122.001208_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3892\/mmr.2020.11694","article-title":"AMPK-SIRT1 pathway dysfunction contributes to neuron apoptosis and cognitive impairment induced by sevoflurane","volume":"23","author":"Liu","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1124\/jpet.122.001208_bib24","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/hmg\/ddt186","article-title":"Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy","volume":"22","author":"L\u00f3pez-Erauskin","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib25","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jcb.26295","article-title":"Inflammatory profile in X-linked adrenoleukodystrophy patients: understanding disease progression","volume":"119","author":"Marchetti","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1124\/jpet.122.001208_bib26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/MCB.23.2.744-753.2003","article-title":"Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy","volume":"23","author":"McGuinness","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.122.001208_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001208_bib28","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/brain\/awt143","article-title":"Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy","volume":"136","author":"Morat\u00f3","year":"2013","journal-title":"Brain"},{"key":"10.1124\/jpet.122.001208_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/brain\/120.8.1485","article-title":"Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy","volume":"120","author":"Moser","year":"1997","journal-title":"Brain"},{"key":"10.1124\/jpet.122.001208_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1212\/WNL.31.10.1241","article-title":"Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids","volume":"31","author":"Moser","year":"1981","journal-title":"Neurology"},{"key":"10.1124\/jpet.122.001208_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/8.5.907","article-title":"Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy","volume":"8","author":"Netik","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib32","first-page":"181","article-title":"Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex)","volume":"4","author":"Powers","year":"1985","journal-title":"Clin Neuropathol"},{"key":"10.1124\/jpet.122.001208_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jnen\/59.2.89","article-title":"Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy","volume":"59","author":"Powers","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/jpet.122.001208_bib34","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1093\/hmg\/ddh323","article-title":"Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy","volume":"13","author":"Pujol","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/11.5.499","article-title":"Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy","volume":"11","author":"Pujol","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib36","doi-asserted-by":"crossref","first-page":"15093","DOI":"10.1038\/s41598-020-71248-8","article-title":"Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-adrenoleukodystrophy","volume":"10","author":"Rattay","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001208_bib37","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/ajmg.a.61641","article-title":"Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing","volume":"182","author":"Schmidt","year":"2020","journal-title":"Am J Med Genet A"},{"key":"10.1124\/jpet.122.001208_bib38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1750-3639.2010.00392.x","article-title":"Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis","volume":"20","author":"Singh","year":"2010","journal-title":"Brain Pathol"},{"key":"10.1124\/jpet.122.001208_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bbrc.2014.01.126","article-title":"Loss of AMP-activated protein kinase in X-linked adrenoleukodystrophy patient-derived fibroblasts and lymphocytes","volume":"445","author":"Singh","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001208_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1194\/jlr.M800321-JLR200","article-title":"Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy","volume":"50","author":"Singh","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.122.001208_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jnc.13562","article-title":"Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase","volume":"138","author":"Singh","year":"2016","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.122.001208_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/176983","article-title":"Loss of AMP-activated protein kinase induces mitochondrial dysfunction and proinflammatory response in unstimulated Abcd1-knockout mice mixed glial cells","volume":"2015","author":"Singh","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1124\/jpet.122.001208_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.122.001208_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jdn.10003","article-title":"X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies","volume":"80","author":"Turk","year":"2020","journal-title":"Int J Dev Neurosci"},{"key":"10.1124\/jpet.122.001208_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1096-7192(03)00098-2","article-title":"Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry","volume":"79","author":"Valianpour","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1124\/jpet.122.001208_bib46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/jpet.122.001208_bib47","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1093\/hmg\/ddt645","article-title":"X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes","volume":"23","author":"Weber","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.122.001208_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jnc.13594","article-title":"The ABCD\u2019s of 5\u2032-adenosine monophosphate-activated protein kinase and adrenoleukodystrophy","volume":"138","author":"Weidling","year":"2016","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.122.001208_bib49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajmg.a.61171","article-title":"A report on state-wide implementation of newborn screening for X-linked adrenoleukodystrophy","volume":"179","author":"Wiens","year":"2019","journal-title":"Am J Med Genet A"},{"key":"10.1124\/jpet.122.001208_bib50","first-page":"109","article-title":"The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis","volume":"8","author":"Wiesinger","year":"2015","journal-title":"Appl Clin Genet"},{"key":"10.1124\/jpet.122.001208_bib51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:57:40Z","timestamp":1743145060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652400301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S002235652400301X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001208","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}